NCT05745740 2023-11-27
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RemeGen Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
8 trialsNCT03863223 2022-11-23
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02973737 2022-10-25
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03980054 2021-05-24
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02500199 2021-02-01
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Hengrui Therapeutics, Inc.
Phase 1 Unknown
NCT03080805 2020-06-18
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02422199 2018-07-09
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT02378389 2015-03-04
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown